In 272 patients aged 5-49 with Ewing or Ewing-like sarcoma, adding zoledronic acid to consolidation chemotherapy did not improve event-free survival vs no zoledronic acid (3-year EFS 59% vs 57%; HR 0.92, 95% CI 0.64-1.31). 3-year overall survival was 75% in both.
RCTn = 272
Bernadette et al. Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial